Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
Cholangiocyte biology in primary sclerosing cholangitis and other cholangiopathies: pathogenesis, clinical insights, and experimental tools.
Journal: Physiological reviews
Published: April 13, 2026
Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial.
Journal: The American journal of gastroenterology
Published: January 14, 2026
Gallbladder neoplasia is associated with a higher incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Journal: Canadian liver journal
Published: October 28, 2025
Microbial Monotherapy With Leuconostoc sp LB-P8 Improves Inflammation and Fibrosis in Mouse Primary Sclerosing Cholangitis by Inhibiting Transforming Growth Factor β1/SMAD Signaling.
Journal: Cellular and molecular gastroenterology and hepatology
Published: October 20, 2025
Lipidomic characterization of bile and serum reveals an altered lipid landscape in end-stage primary sclerosing cholangitis.
Journal: Scientific reports
Published: October 09, 2025
Dynamic cholangiocyte responses in a murine model of reversible cholestasis: macrophage remodeling and NF-Y-mediated TGFβ1 expression.
Journal: American journal of physiology. Gastrointestinal and liver physiology
Published: September 29, 2025
Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression.
Journal: Journal of gastroenterology and hepatology
Published: July 25, 2025
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.
Journal: Hepatology (Baltimore, Md.)
Published: July 25, 2025
Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.
Journal: Hepatology (Baltimore, Md.)
Published: December 11, 2024
Targeting of a Bile Acid Receptor, Takeda G Protein Receptor 5 [TGR5], by a Novel First-in-Class Competitive Antagonist, SBI-364, Diminishes Hepatic and Renal Cystogenesis in Polycystic Liver and Kidney Disease.
Journal: ACS pharmacology & translational science
Published: December 02, 2024
Last Updated: 09/26/2026